Brokerages Expect Insulet Co. (PODD) Will Announce Quarterly Sales of $125.25 Million

Wall Street brokerages expect Insulet Co. (NASDAQ:PODD) to post $125.25 million in sales for the current quarter, according to Zacks Investment Research. Ten analysts have made estimates for Insulet’s earnings. The highest sales estimate is $127.49 million and the lowest is $124.20 million. Insulet reported sales of $103.58 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 20.9%. The firm is scheduled to announce its next earnings report after the market closes on Wednesday, February 21st.

According to Zacks, analysts expect that Insulet will report full-year sales of $125.25 million for the current year, with estimates ranging from $457.40 million to $460.79 million. For the next financial year, analysts forecast that the company will report sales of $556.15 million per share, with estimates ranging from $510.43 million to $588.51 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research analysts that that provide coverage for Insulet.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.06. The firm had revenue of $121.80 million for the quarter, compared to analysts’ expectations of $114.02 million. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The company’s revenue for the quarter was up 28.4% compared to the same quarter last year. During the same quarter last year, the business posted ($0.05) earnings per share.

Several equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of Insulet from a “hold” rating to a “sell” rating in a research report on Tuesday, January 9th. BidaskClub upgraded shares of Insulet from a “sell” rating to a “hold” rating in a research report on Friday. Barclays boosted their price target on shares of Insulet from $70.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, November 20th. UBS Group upgraded shares of Insulet from a “market perform” rating to an “outperform” rating in a research report on Monday, January 8th. Finally, Raymond James Financial upgraded shares of Insulet from a “market perform” rating to an “outperform” rating and set a $80.00 price target on the stock in a research report on Monday, January 8th. One equities research analyst has rated the stock with a sell rating, seven have assigned a hold rating and twelve have given a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $62.53.

In other news, Director James C. Mullen bought 2,500 shares of the stock in a transaction that occurred on Monday, November 13th. The stock was bought at an average cost of $67.45 per share, for a total transaction of $168,625.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Company insiders own 2.60% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Capital Research Global Investors increased its position in Insulet by 2.5% during the second quarter. Capital Research Global Investors now owns 5,883,633 shares of the medical instruments supplier’s stock worth $301,889,000 after buying an additional 145,724 shares during the period. Vanguard Group Inc. raised its position in shares of Insulet by 2.2% during the 2nd quarter. Vanguard Group Inc. now owns 4,655,119 shares of the medical instruments supplier’s stock worth $238,854,000 after purchasing an additional 98,272 shares during the period. Frontier Capital Management Co. LLC raised its position in shares of Insulet by 42.4% during the 4th quarter. Frontier Capital Management Co. LLC now owns 2,096,131 shares of the medical instruments supplier’s stock worth $144,633,000 after purchasing an additional 624,465 shares during the period. Fred Alger Management Inc. increased its position in Insulet by 4.2% in the 2nd quarter. Fred Alger Management Inc. now owns 1,264,025 shares of the medical instruments supplier’s stock valued at $64,857,000 after acquiring an additional 50,780 shares during the period. Finally, State Street Corp increased its position in Insulet by 7.7% in the 2nd quarter. State Street Corp now owns 1,189,155 shares of the medical instruments supplier’s stock valued at $61,014,000 after acquiring an additional 85,280 shares during the period.

Insulet (NASDAQ:PODD) traded up $0.02 during trading on Friday, hitting $78.08. 122,017 shares of the stock traded hands, compared to its average volume of 560,357. The company has a market capitalization of $4,524.68, a PE ratio of -156.16 and a beta of 1.58. The company has a debt-to-equity ratio of 4.65, a quick ratio of 4.42 and a current ratio of 4.88. Insulet has a 52-week low of $38.43 and a 52-week high of $78.65.

COPYRIGHT VIOLATION WARNING: This article was first reported by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/01/28/brokerages-anticipate-insulet-co-podd-will-post-quarterly-sales-of-125-25-million-2.html.

Insulet Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the Omnipod Insulin Management System (the Omnipod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Get a free copy of the Zacks research report on Insulet (PODD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply